Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.

Biotechnology

Allogene Therapeutics

Allogene Therapeutics' headquarters in South San Francisco, CA, United States

The Newark office focuses on quality assurance and manufacturing support in the biotechnology and pharmaceutical sectors.

People (4)

Jobs (0)

Other offices